Thalassemia
Open Access
- 1 January 2004
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2004 (1) , 14-34
- https://doi.org/10.1182/asheducation-2004.1.14
Abstract
New developments in the epidemiology, treatment and prognosis of thalassemia have dramatically altered the approach to the care of affected patients, and these developments are likely to have an even greater impact in the next few years. Demographic changes have required an awareness and understanding of the unique features of thalassemia disorders that were previously uncommon in North America but are now seen more frequently in children and recognized more consistently in adults. New methods for measuring tissue iron accumulation and new drugs to remove excessive iron are advancing two of the most challenging areas in the management of thalassemia as well as other transfusion-dependent disorders. Improved survival of patients with thalassemia has given new importance to adult complications such as endocrinopathies and hepatitis that have a major impact on the quality of life. This chapter describes how these changes are redefining the clinical management of thalassemia.Keywords
This publication has 71 references indexed in Scilit:
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell DiseaseNew England Journal of Medicine, 2004
- Iron/Bone marrow failureThe Hematology Journal, 2004
- Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemiaJournal of Magnetic Resonance Imaging, 2003
- Role of deferiprone in chelation therapy for transfusional iron overloadBlood, 2003
- Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron poolBlood, 2003
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- Extramedullary haemopoiesis in haemoglobin E/β-thalassaemiaBritish Journal of Haematology, 2003
- Iron Deficiency and OverloadHematology-American Society Hematology Education Program, 2003
- Genetic and Clinical Features of Hemoglobin H Disease in Chinese PatientsNew England Journal of Medicine, 2000